TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05435053

Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.
“The study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study.”

The sponsor’s own words in the registry.

Life of this trial

202220232024Registered2022-06-22Started2022-09-08Stopped2023-08-30

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Ismail Gögenur
Sponsor type
University, hospital or other
Conditions
Pancreas Cancer
Interventions
Nivolumab; Irreversible electroporation (IRE)
Participants
9
Sites
1
Countries
Denmark

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.